These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 15282866)
1. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. Dezube BJ; Aboulafia DM; Pantanowitz L AIDS Read; 2004 Jul; 14(7):372-4, 377-9. PubMed ID: 15282866 [TBL] [Abstract][Full Text] [Related]
2. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491 [TBL] [Abstract][Full Text] [Related]
3. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903 [TBL] [Abstract][Full Text] [Related]
4. Management of newly diagnosed myeloma. Rajkumar SV; Palumbo A Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Jimenez-Zepeda VH; Heilman RL; Engel RA; Carey EJ; Freeman C; Rakela J; Mulligan DC; Fonseca R; Stewart AK Transplantation; 2011 Sep; 92(5):570-4. PubMed ID: 21712755 [TBL] [Abstract][Full Text] [Related]
6. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204 [TBL] [Abstract][Full Text] [Related]
7. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. Kristinsson SY; Björkholm M; Schulman S; Landgren O Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658 [TBL] [Abstract][Full Text] [Related]
12. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. Aboulafia DM AIDS Read; 2003 Aug; 13(8):383-9. PubMed ID: 14524324 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438 [TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]